62 163

Cited 0 times in

Randomized Trial of Prophylactic Antibiotics for Endoscopic Retrograde Cholangiopancreatography in Patients With Biliary Obstruction

DC Field Value Language
dc.contributor.author구남수-
dc.contributor.author박승우-
dc.contributor.author박정엽-
dc.contributor.author방승민-
dc.contributor.author이희승-
dc.contributor.author정문재-
dc.contributor.author조중현-
dc.contributor.author임가람-
dc.contributor.author박지훈-
dc.contributor.author송시영-
dc.date.accessioned2024-03-22T06:47:50Z-
dc.date.available2024-03-22T06:47:50Z-
dc.date.issued2024-01-
dc.identifier.issn0002-9270-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/198624-
dc.description.abstractINTRODUCTION: The incidence of postendoscopic retrograde cholangiopancreatography (ERCP) infections is reported to be up to 18% in patients with biliary obstruction. Antibiotic prophylaxis may reduce the risk of infectious complications after ERCP; however, the clinical value of prophylactic antibiotics in ERCP remains controversial. METHODS: We conducted a double-blind, placebo-controlled, randomized trial to investigate whether the use of prophylactic antibiotics would reduce infectious complications after ERCP in patients with biliary obstruction. We randomly assigned patients in a 1:1 ratio to receive either a single dose of 1 g intravenous cefoxitin or normal saline as a placebo 30 minutes before undergoing ERCP. The primary outcome was the incidence of infectious complications after ERCP. RESULTS: We enrolled 378 patients, and 189 patients were assigned to each group. The risk of infectious complications after ERCP was 2.8% (5 of 176 patients) in the antibiotic prophylaxis group and 9.8% (17 of 173 patients) in the placebo group (risk ratio, 0.29; 95% confidence interval [CI], 0.11-0.74, P = 0.0073). The incidence rates of bacteremia were 2.3% (4 of 176 patients) and 6.4% (11 of 173 patients), respectively (risk ratio, 0.36; 95% CI, 0.12-1.04; P = 0.0599). The incidence rate of cholangitis was 1.7% (3 of 176 patients) in the antibiotic prophylaxis group and 6.4% (11 of 173 patients) in the placebo group (risk ratio, 0.27; 95% CI, 0.08-0.87; P = 0.0267). DISCUSSION: Antibiotic prophylaxis before ERCP in patients with biliary obstruction resulted in a significantly lower risk of infectious complications, especially cholangitis, than placebo ( ClinicalTrials.gov trial number NCT02958059). Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology.-
dc.description.statementOfResponsibilityopen-
dc.formatapplication/pdf-
dc.languageEnglish-
dc.publisherNature Pub. Group-
dc.relation.isPartOfAMERICAN JOURNAL OF GASTROENTEROLOGY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.subject.MESHAnti-Bacterial Agents / therapeutic use-
dc.subject.MESHAntibiotic Prophylaxis / adverse effects-
dc.subject.MESHCholangiopancreatography, Endoscopic Retrograde / adverse effects-
dc.subject.MESHCholangitis* / epidemiology-
dc.subject.MESHCholangitis* / etiology-
dc.subject.MESHCholangitis* / prevention & control-
dc.subject.MESHCholestasis* / complications-
dc.subject.MESHCholestasis* / prevention & control-
dc.subject.MESHHumans-
dc.titleRandomized Trial of Prophylactic Antibiotics for Endoscopic Retrograde Cholangiopancreatography in Patients With Biliary Obstruction-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학교실)-
dc.contributor.googleauthorGalam Leem-
dc.contributor.googleauthorMin Je Sung-
dc.contributor.googleauthorJi Hoon Park-
dc.contributor.googleauthorSo Jeong Kim-
dc.contributor.googleauthorJung Hyun Jo-
dc.contributor.googleauthorHee Seung Lee-
dc.contributor.googleauthorNam Su Ku-
dc.contributor.googleauthorJeong Youp Park-
dc.contributor.googleauthorSeungmin Bang-
dc.contributor.googleauthorSeung Woo Park-
dc.contributor.googleauthorSi Young Song-
dc.contributor.googleauthorMoon Jae Chung-
dc.identifier.doi10.14309/ajg.0000000000002495-
dc.contributor.localIdA00189-
dc.contributor.localIdA01551-
dc.contributor.localIdA01647-
dc.contributor.localIdA01786-
dc.contributor.localIdA03349-
dc.contributor.localIdA03602-
dc.contributor.localIdA03912-
dc.relation.journalcodeJ00081-
dc.identifier.eissn1572-0241-
dc.identifier.pmid37713527-
dc.contributor.alternativeNameKu, Nam Su-
dc.contributor.affiliatedAuthor구남수-
dc.contributor.affiliatedAuthor박승우-
dc.contributor.affiliatedAuthor박정엽-
dc.contributor.affiliatedAuthor방승민-
dc.contributor.affiliatedAuthor이희승-
dc.contributor.affiliatedAuthor정문재-
dc.contributor.affiliatedAuthor조중현-
dc.citation.volume119-
dc.citation.number1-
dc.citation.startPage183-
dc.citation.endPage190-
dc.identifier.bibliographicCitationAMERICAN JOURNAL OF GASTROENTEROLOGY, Vol.119(1) : 183-190, 2024-01-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.